An Open Label,Observational, Real Time Data Capturing of Usage & Outcome of Coseal
NCT ID: NCT01706640
Last Updated: 2012-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
750 participants
OBSERVATIONAL
2012-12-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective of this study is to assess current practice pattern and best practice sharing of usage of Coseal by collecting data on (1) Sealing suture lines along arterial and venous reconstruction(2) Patients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture lines in lung resection procedures (3) From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery.
Number of expected patient enrollment is 750 from 20 participating sites.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Assessing current practice pattern and best practice sharing of usage of Coseal as per IFU by collecting data on oSealing suture lines along arterial and venous reconstructions oPatients undergoing cardiac surgery to prevent or reduce the incidence, severity and extent of post surgical adhesion enforcement of suture and staple lines in lung resection procedures
* From this data to document and generate a real life experience on the use of Coseal in cardio vascular and thoracic surgery
* To possibly create a guideline for usage of Sealant in routine practice in India
* To study delivery methods and clinical impact in minimally invasive surgery like VATS and robotic surgery
End points
Primary Endpoint
1. Cardio vascular sealing:
To report the effectiveness and safety of COSEAL in the control of anastomotic suture line and needle hole suture bleeding during vascular reconstruction by checking the incidence of immediate anastomotic sealing and the presence of persistent intra-operative and postoperative bleeding average time to achieve hemostasis for a single bleeding site after 60 s of clamping without manual compression In case of sternotomy, Hemostasis time in mns, which is operative time comprised between the removal of cardio-pulmonary bypass cannulae and the closure of the sternum.
Overall postoperative bleeding in mL/m² revision for bleeding Minor complications, major complications, mortality
2. Efficacy of Coseal in prevention or reduction of adhesion in re-do surgeries for patients with staged operations for congenital cardiac malformation re-operated on during the follow-up period of the registry
Incidence of adhesions. location and extension of adhesion by measuring the percentage of surface affected for each of the following regions: pericardial or retrosternal, inferior or diaphragmatic region, right lateral or atrial region, region around the great vessels, pulmonary surface.
Overall evaluation (dissection easy or difficult) Incidence of subjects free of adhesions.
Severity (at each of these sites, the adhesions will be graded as follows:
absence of adhesion; 1: filmy and avascular; 2: dense and/or vascular; and 3: cohesive)
3. Air leak: incidence of immediate (at the time of closure) and prolonged post-operative air leak, Use in redo surgery for air leak.
Secondary Endpoints
1. Cardiovascular (sealing and adhesion prevention):
1. Total operative time
2. Nature and duration of first operation
3. Nature and duration of redo operation, and time for dissection from sternotomy to end of dissection for prevention of adhesions )
4. Length of intensive care stay
5. Length of hospital stay
6. Infection rate
7. Quality of wound healing
8. Quality of life (SF36)
2. Thoracic and Lung
1. Sealing the suture/ staple line on table Use of buttressing
2. Total operative time
3. Drain output
4. Drain duration
5. Length of hospital stay
6. Prolonged air leak (more than 5 days) (\>5 days is the new standard for prolonged aire leak accepted in 2011 by the EU Soc of CVTS, see ref.)
7. Infection rate
3. In all cases,
1. intra and post-operative blood loss
2. FFP, Transfusion
3. Reoperation for bleeding purpose
4. Others
1. Surgeons satisfaction
2. Easiness of product handling during application (VAS)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient undergoing open, Video Assisted surgery and robotic surgery to be included and analysed as subgroups
3. Written informed consent obtained from the patient or legal representative for data collection post surgery in patients who had Coseal used intraoperatively (data privacy laws).
Exclusion Criteria
2. Known Immune system disorders, immunodeficiency
3. Concomitant use of any other anti-adhesion product
4. Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
5. Unplanned re-operation in case of use for anti-adhesion
6. Contraindications for use of Coseal
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medanta, The Medicity, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Ali Zamir Khan
Head of Department, Minimally Invasive & Robotic Thoracic Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Ali Z Khan, MS,FRCS,FRCS
Role: PRINCIPAL_INVESTIGATOR
Medanta, The Medicity
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medanta, The Medicity
Gurgaon, Haryana, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MM/CTVS/2012/001
Identifier Type: -
Identifier Source: org_study_id